China channel feed

Spot­ting a gem from transpa­cif­ic biotech, As­traZeneca pays $25M cash to pick up a pre­clin­i­cal bis­pe­cif­ic an­ti­body

4 years ago
Deals

Af­ter steer­ing made-in-Chi­na CAR-T all the way from ob­scu­ri­ty to ap­proval, Frank Fan re­signs from Leg­end

4 years ago
People
Cell/Gene Tx

Har­vard sci­en­tist Charles Lieber seeks ac­quit­tal in 'ill-con­ceived' Chi­na Ini­tia­tive case

4 years ago
People
Law

Most Chi­nese firms could keep their US list­ings un­der draft frame­work — re­port

4 years ago
Pharma

Up­dat­ed: SEC chair de­nies a deal to pre­vent Chi­nese com­pa­ny delist­ing is close — re­ports

4 years ago
Pharma

As brand­ed drug sales surge, an­a­lysts pre­dict Chi­na mar­ket will re­main 'very at­trac­tive'

4 years ago
Pharma

Small RSV con­tender eyes 'first-to-mar­ket' op­por­tu­ni­ty with $225M Asia deal

4 years ago
Deals

Chi­na work­ing on con­ces­sions to help home­grown com­pa­nies stay on US ex­changes — re­port

4 years ago
FDA+

SEC sin­gles out Zai Lab, BeiGene, Hutchmed for reg­u­la­to­ry scruti­ny — with threats of delist­ing

4 years ago
FDA+

With all eyes on Chi­nese-on­ly on­col­o­gy da­ta, Co­herus and Jun­shi un­cork win for PD-1 drug in esophageal can­cer

4 years ago
R&D

DOJ scraps di­vi­sive Chi­na Ini­tia­tive that swept up promi­nent sci­en­tists — but vows to keep guard­ing against aca­d­e­m­ic es­pi­onage

4 years ago
People

Af­ter Lil­ly's sin­til­imab shel­lack­ing, Chi­na-on­ly on­col­o­gy tri­als are fac­ing a new — and un­fa­vor­able — re­al­i­ty at the FDA

4 years ago
R&D

'Reg­u­la­to­ry flex­i­bil­i­ty is not war­rant­ed': FDA balks at al­low­ing Chi­na-on­ly da­ta for Eli Lil­ly's an­ti-PD-1 an­ti­body

4 years ago
FDA+

Reel­ing from FDA re­jec­tion, Be­yond­Spring ax­es 35% of US staffers in hopes of I/O come­back

4 years ago
People
Pharma

Clover Bio­phar­ma­ceu­ti­cals sets up a new R&D cen­ter in a buzzy Chi­nese hub near Shang­hai

4 years ago
R&D
Manufacturing

Low-pro­file RNAi play­er lands on HKEX fol­low­ing mod­est $50M IPO

4 years ago
Financing

Sutro strikes a $40M Chi­na deal as it looks to push ahead of a crowd­ed pack

4 years ago
Deals

'He re­peat­ed­ly lied': Feds pile on as Har­vard chemist Charles Lieber con­vict­ed of ly­ing about Chi­nese ties

4 years ago
People

No­var­tis turns to BeiGene again for the next big check­point tar­get, pay­ing $300M to jump in­to TIG­IT race

4 years ago
Deals

US black­lists Chi­nese re­search in­sti­tutes over 'brain con­trol' ef­forts as in­vestor frets roil biotech stocks

4 years ago
Pharma

Un­co­or­di­nat­ed and re­dun­dant: FDA's Paz­dur slams check­point in­hibitor de­vel­op­ers for cre­at­ing a 'Wild West'

4 years ago
R&D
FDA+

Lin­ing up a fil­ing for lead ROS1 in­hibitor, transpa­cif­ic on­col­o­gy biotech An­Heart Ther­a­peu­tics rais­es $61M

4 years ago
Financing

Qim­ing-backed CAN­bridge gets its Hong Kong IPO as Nas­daq slow­down prompts re­newed mar­ket analy­sis

4 years ago
Financing

Vi­vo Cap­i­tal, Bain, Pri­mav­era pour $200M in­to vir­tu­al­ly un­known tar­get­ed on­col­o­gy play out of Chi­na

4 years ago
Financing
First page Previous page 10111213141516 Next page Last page
A service from the Financial Times